Search Results
Results found for "Haicang Zhang"
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
assays to monitor β-arrestin recruitment or signaling, and assays to monitor receptor conformational changes
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
“You’re not changing the spectrum,” Trinquet explains. “You’re changing how bright it is—and how long it glows.”
- Combined docking and machine learning identify key molecular determinants of ligand pharmacological
allowed us to construct an exquisitely detailed structure‐activity relationship that identifies small changes
- Effect Delta-9-tetrahydrocannabinol and cannabidiol on milk proteins and lipid levels in HC11 cells
this study, we investigated the effects of THC and CBD on the differentiation of MECs by assessing changes
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
as this was the first description of ACKR1 expression by any leukocyte type and, if correct, would change
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
Ya-Tzu Li , our notable contributor, for her superb undergrad paper along with Hao-Jen Hsu , Chun-Chun Chang Drugs like Ozempic will change the world GPCR Events, Meetings, and Webinars November 5 - 7, 2024 | 16th
- Biphasic activation of β-arrestin 1 upon interaction with a GPCR revealed by methyl-TROSY NMR
Here, we show the conformational changes for βarr activation upon the C tail- and TM core-mediated interactions
- GPCR Happy Hour – Boston, Sept 2025
America, NIS delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing
- G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease..
The changes in amyloid pathology are accompanied by robust microglial and astrocytic hypertrophy, which
- Phospholipid Scrambling by G Protein-Coupled Receptors
Conformational changes that facilitate scrambling are distinct from those associated with GPCR signaling
- Newly launched antibody libraries put hard-to-drug targets within reach
The drugs also target relatively low-hanging fruit: like cytokines or tyrosine kinase receptors.
- Canonical chemokine receptors as scavenging “decoys”
2000), becoming incapable of promoting cell migration, a phenomenon which is likely to be mediated by changes
- How Fast Does a Drug Work?
Competitive conditions —such as the presence of endogenous ligands— change kinetic behavior , and ignoring
- Radioligands vs. Fluorescent Ligands: Binding Assays
with a higher specific activity, but a shorter half-life (60 days), which complicates storage, besides changing
- GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between ...
molecular diversity of GPCR signaling systems is likely to be closely associated with disease-associated changes
- Ode to GPCRs
Zhang, X. & Eggert, U. S.
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
Why this matters: Membrane context changes signaling outcomes.
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
/no-go choices Strategic insights into early identification and mitigation of drug liabilities Game-Changing
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
In all cases, the receptor interaction changes downstream signalling and the responses to receptor agonists
- How Schild Analysis Protects Your Conclusions in GPCR Research
Anyone who joins before the change is fully grandfathered — your rate stays locked, and your whole team
- Structural dynamics of Smoothened (SMO) in ciliary membrane and its interaction with membrane lipids
Structural analysis of SMO domains shows significant changes in the CRD and ICD, during the course of
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
Target Engagement—Don’t Chase It with Irreversible Drugs When binding outlives exposure, everything changes
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
. 🎧 Go behind the scenes with Revvity —from the chemistry to the critical moments that changed everything
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
Every time a problem arises, we trace it back to its root cause, implementing changes that prevent its
- Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor
Here, we investigate the conformational changes induced by the binding of a nanobody (Nb80) on the active-like
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
Crucially, altering one does not inherently change the others—a principle often overlooked in early discovery
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
Seeing that probe expose receptor distribution across an entire native islet changed what they believed
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
This paper thoroughly investigated the role of single amino acid changes to clarify the molecular mechanisms
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
clarity—so you can pick better targets, stress-test hypotheses earlier, and focus on experiments that change
- The Five Traps of Ignoring Kinetics
That’s where Terry’s Corner changes the game.
















